BASKING RIDGE, N.J., Sept. 9 /PRNewswire/ -- Regado Biosciences, a privately
held company leading the development of antithrombotic therapeutic aptamers
with active control agents, announced that on September 8, 2009 enrollment of
the first patient in a Phase 2b, randomized, partially-blinded, multi-center,
active-controlled, dose-ranging study of its lead product candidate, the REG1
anticoagulation system (REG1) was achieved. REG1 comprises the selective
factor IXa inhibitor, RB006, and its specific active control agent, RB007. The
trial, called RADAR, will assess the safety, efficacy, and pharmacodynamics of
REG1 compared to unfractionated heparin or low molecular weight heparin in
subjects with acute coronary syndromes (ACS). Regado recently successfully
completed a phase 2a study of REG1 in stable coronary artery disease patients
undergoing elective PCI.
